FirstinHuman

ST. LOUIS, June 15, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it intends to initiate a first-in-human trial…

PHILADELPHIA, June 05, 2023 (GLOBE NEWSWIRE) -- Enterin Inc., a privately held, Philadelphia-based, clinical-stage biopharmaceutical company pioneering novel treatments for neurodegenerative and metabolic diseases, today announced the…

<!-- Name:DistributionId Value:8808267 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4573 -->…

<!-- Name:DistributionId Value:1000800550 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:5555 -->…

<!-- Name:DistributionId Value:8744827 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4570 -->…

<!-- Name:DistributionId Value:8741962 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4577 -->…

A newly published paper in The Lancet shows that an experimental vaccine against Marburg virus (MARV) was safe and induced an immune response in a small, first-in-human clinical trial. The vaccine, developed by researchers at the National…

- Lead compound IOS-1002 to be studied as mono and combination therapy in patients with advanced solid tumors- First patients to be enrolled in Q1, 2023 Schlieren (Zurich Area), Switzerland – January 17, 2023 – ImmunOs Therapeutics…

BOSTON, Dec. 29, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, announced today that it has received written…

While scientists have struggled in the past to create an effective vaccine against HIV, a novel vaccine design strategy being pursued by researchers at Scripps Research, IAVI, Fred Hutchinson Cancer Center (Fred Hutch) and the National…